Drs. Stephen Harrison and W. Ray Kim discuss the paper: Model to
estimate survival in ambulatory patients with hepatocellular carcinoma.
Source - http://www.aasld.org/journals/hepatology/Pages/kimpodcast.aspx
Listen Now via LiverLearning® or
Play in browser/download above
Abstract
Survival of patients with hepatocellular carcinoma (HCC) is
determined by the extent of the tumor and the underlying liver function. We
aimed to develop a survival model for HCC based on objective parameters
including the Model for Endstage Liver Disease (MELD) as a gauge of liver
dysfunction. This analysis is based on 477 patients with HCC seen at Mayo Clinic
Rochester between 1994 and 2008 (derivation cohort) and 904 patients at the
Korean National Cancer Center between 2000 and 2003 (validation cohort).
Multivariate proportional hazards models and corresponding risk score were
created based on baseline demographic, clinical, and tumor characteristics.
Internal and external validation of the model was performed. Discrimination and
calibration of this new model were compared against existing models including
Barcelona Clinic Liver Cancer (BCLC), Cancer of the Liver Italian Program
(CLIP), and Japan Integrated Staging (JIS) scores. The majority of the patients
had viral hepatitis as the underlying liver disease (100% in the derivation
cohort and 85% in the validation cohort). The survival model incorporated MELD,
age, number of tumor nodules, size of the largest nodule, vascular invasion,
metastasis, serum albumin, and alpha-fetoprotein. In cross-validation, the
coefficients remained largely unchanged between iterations. Observed survival in
the validation cohort matched closely with what was predicted by the model. The
concordance (c)-statistic for this model (0.77) was superior to that for BCLC
(0.71), CLIP (0.70), or JIS (0.70). The score was able to further classify
patient survival within each stage of the BCLC classification. Conclusion: A new
model to predict survival of HCC patients based on objective parameters provides
refined prognostication and supplements the BCLC classification.
This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment